Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
INB-400 in Glioblastoma, IDH-Wildtype: NCT05664243 Clinical Landscape Report 2026
16 October 2026
NCT05664243 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Recurrent Glioblastoma: NCT05663125 Clinical Landscape Report 2026
16 October 2026
NCT05663125 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Niraparib Tosylate in Recurrent Glioblastoma: NCT05666349 Clinical Landscape Report 2026
16 October 2026
NCT05666349 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT05685004 Clinical Landscape Report 2026
16 October 2026
NCT05685004 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Apixaban in Glioblastoma: NCT05683808 Clinical Landscape Report 2026
16 October 2026
NCT05683808 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
QRL-101 in Amyotrophic Lateral Sclerosis: NCT05667779 Clinical Landscape Report 2026
16 October 2026
NCT05667779 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
WVE-004 in Frontotemporal Dementia: NCT05683860 Clinical Landscape Report 2026
16 October 2026
NCT05683860 clinical landscape for Frontotemporal Dementia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ad5-yCD/mutTKSR39rep-hIL12 in Astrocytoma: NCT05686798 Clinical Landscape Report 2026
16 October 2026
NCT05686798 clinical landscape for Astrocytoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
64Cu-ATSM in Neurodegenerative Diseases: ACTRN12623000067673 Clinical Landscape Report 2026
16 October 2026
ACTRN12623000067673 clinical landscape for Neurodegenerative Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Etoposide in Glioblastoma: NCT05694416 Clinical Landscape Report 2026
16 October 2026
NCT05694416 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CK-0803 in Amyotrophic Lateral Sclerosis: NCT05695521 Clinical Landscape Report 2026
16 October 2026
NCT05695521 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Gliosarcoma: NCT05698524 Clinical Landscape Report 2026
16 October 2026
NCT05698524 clinical landscape for Gliosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.